** Kura Oncology KURA.O shares jump 14% to $6.49 in pre-market trading

** KURA and Japan-based Kyowa Kirin 4151.T say the US FDA accepted marketing application for ziftomenib

** The drug, if approved, could be used to treat patients with acute myeloid leukemia, a type of blood cancer

** The disease affects about 22,000 people in the US every year, according to American Cancer Society

** Ziftomenib is a potential first-of-its-kind treatment for this aggressive form of leukemia, the cos say

** The FDA has granted priority review and is likely to decide by November 30 this year, they added

** YTD, stock down 34.7%, as of last close

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))